Harvey Capital Management Inc. Has $8.87 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Harvey Capital Management Inc. lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% during the 4th quarter, HoldingsChannel reports. The fund owned 185,435 shares of the biopharmaceutical company’s stock after selling 425 shares during the period. Halozyme Therapeutics accounts for approximately 2.1% of Harvey Capital Management Inc.’s portfolio, making the stock its 12th biggest holding. Harvey Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $8,866,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $29,000. GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $57,000. FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $65,000. Finally, CWM LLC increased its stake in shares of Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 668 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $57.33 on Wednesday. The company has a market capitalization of $7.29 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $34.36 and a one year high of $65.53. The company’s fifty day moving average price is $51.90 and its 200 day moving average price is $54.42.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on HALO shares. JMP Securities lifted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Finally, Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.